Get started
KNIGHT THERAPEUTICS INCKNIGHT THERAPEUTICS INCKNIGHT THERAPEUTICS INC

KNIGHT THERAPEUTICS INC

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

GUD chart

Key stats

Market capitalization
‪576.67 M‬CAD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.17CAD
Net income
‪−16.84 M‬CAD
Revenue
‪328.20 M‬CAD
Shares float
‪65.08 M‬
Beta (1Y)
0.16

About KNIGHT THERAPEUTICS INC

Sector
Health Technology
CEO
Samira Sakhia
Headquarters
Montréal
Website
gud-knight.com
Employees (FY)
725
Founded
2013
ISIN
CA4990531069
FIGI
BBG006373G71
Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The firm also focuses on building a portfolio of innovative products through in-licensing or acquiring product rights. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montréal, Canada.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of GUD is 5.76 CAD — it has increased by 1.05% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TSX exchange KNIGHT THERAPEUTICS INC stocks are traded under the ticker GUD.
KNIGHT THERAPEUTICS INC is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for KNIGHT THERAPEUTICS INC has a max estimate of 7.60 CAD and a min estimate of 5.25 CAD.
GUD earnings for the last quarter are 0.09 CAD whereas the estimation was −0.03 CAD which accounts for 377.16% surprise. Estimated earnings for the next quarter are −0.01 CAD. See more details about KNIGHT THERAPEUTICS INC earnings.
KNIGHT THERAPEUTICS INC revenue for the last quarter amounts to ‪81.50 M‬ CAD despite the estimated figure of ‪73.46 M‬ CAD. In the next quarter revenue is expected to reach ‪78.70 M‬ CAD.
Yes, you can track KNIGHT THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
Like other stocks, GUD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KNIGHT THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
GUD reached its all-time high on Dec 5, 2016 with the price of 11.03 CAD, and its all-time low was 3.51 CAD and was reached on Mar 3, 2014.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has 725.00 employees. See our rating of the largest employees — is KNIGHT THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KNIGHT THERAPEUTICS INC EBITDA is ‪56.82 M‬ CAD, and current EBITDA margin is 17.31%. See more stats in KNIGHT THERAPEUTICS INC financial statements.